DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/j3x4k4/antidepressants) has announced the addition of the "Antidepressants Market to 2018 - Despite Safety Concerns, Selective Serotonin Re-uptake Inhibitors (SSRIs) Continue to Dominate in the Absence of Effective Therapeutic Alternatives" report to their offering.
Considerable Scope for Improvement' in Antidepressants Market, Says Report
Further research into the disease etiology of a number of mental health disorders would open up considerable scope for improvement in the development of antidepressants, says a new report by GBI Research.
The report* states that the global antidepressants market for Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Generalized Anxiety Disorder (GAD) and Panic Disorder (PD) - estimated at $11.9 billion in 2011 - is forecast to generate $13.4 billion by 2018. Antidepressants are among the top three most prescribed classes of drugs in the US, along with cholesterol-lowering drugs and painkillers.
The report states that Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) are the most commonly prescribed classes of antidepressants, but many patients fail to respond adequately to them, while a significant number of patients also discontinue therapy due to negative and unwanted side effects.
Latency is also a factor in drug compliance, as the positive effects of antidepressants may only be seen after around six weeks, leading to more instances of treatment discontinuance due to frustration and lost confidence in the drug. The report estimates that around 25% of patients will stop taking their prescribed medication within the first four weeks of treatment.
The pharmaceutical industry has so far struggled to improve on current antidepressants, partly due to inadequate understanding and the difficulty of conducting clinical trials, according to GBI Research analysis. A notably high placebo effect, and a lack of objective assessment criteria and financing all represent drawbacks for scientific study into antidepressant therapeutics.
Without major breakthroughs in scientific understanding, development activity in this therapeutic area will be restricted. However, this does leave considerable scope for improvement over the current treatment options if understanding of the disease etiology improves.
This report provides an in-depth analysis of the major antidepressants therapies, including SSRIs, Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and Tricyclic Antidepressants (TCAs), covering Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Generalized Anxiety Disorder (GAD) and Panic Disorder (PD). It provides the sales, treatment usage patterns for the global antidepressant market in addition to the individual indication markets.
It also provides the geographical distribution of antidepressants across the US, the top five countries of Europe, and Japan, and gives insights into the antidepressants R&D product pipeline and explores the competitive landscape, including major players in the antidepressants market. Finally, the report also includes analysis on the Mergers and Acquisitions (M&As) and licensing agreements that took place in antidepressant market.
Companies Mentioned:
- H. Lundbeck
- AstraZeneca
- Eli Lilly and Company
- Forest Laboratories
- Pfizer Inc.
- GlaxoSmithKline
- Bristol-Myers Squibb Company
For more information visit http://www.researchandmarkets.com/research/j3x4k4/antidepressants